Deal with ST Japan marks next stage in strategy to penetrate the pharmaceutical, chemical, and biotechnology markets with state-of-the-art software technologies for the analytical lab
Creon Lab Control and ST Japan are to establish and operate a joint venture to serve customers exclusively in the Asian region. The new company will initially establish a sales office to serve the pharmaceutical, chemical, and biotechnology industries as well as the OEM business in these countries.
This new venture, Creon Lab Control Japan, marks the next stage in the ST Japan's strategy to penetrate the market with state-of-the-art software technologies for the analytical laboratory.
At the same time, Creon Lab Control will gain access to customer groups from the life science sector for the increasingly specialised software business.
"This joint venture will enable us to enter a new market in the life science sector.
By combining our strengths, we will be able to use our expertise to optimize customer care and attract new customers." said Kurt Holland-Moritz, member of the board of Creon Lab Control.
"By cooperating with our strong partner Creon Lab Control we expand our activities by a new, attractive business field." comments Takao Nakagawa, president of ST Japan.
